Zura Bio (NASDAQ:ZURA) Trading Down 1.6% – Should You Sell?

Zura Bio Limited (NASDAQ:ZURA)’s share price dropped 1.6% on Friday . The company traded as low as $1.22 and last traded at $1.26. Approximately 142,746 shares traded hands during trading, a decline of 64% from the average daily volume of 391,106 shares. The stock had previously closed at $1.28.

Analyst Upgrades and Downgrades

ZURA has been the topic of a number of recent research reports. HC Wainwright restated a “neutral” rating and set a $5.00 price target on shares of Zura Bio in a report on Tuesday, December 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a report on Wednesday, December 11th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Zura Bio presently has a consensus rating of “Buy” and an average target price of $15.80.

Zura Bio Stock Down 1.6 %

The firm’s fifty day moving average is $1.73 and its 200 day moving average is $2.99.

Institutional Trading of Zura Bio

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC grew its position in Zura Bio by 70.6% in the 3rd quarter. Geode Capital Management LLC now owns 912,625 shares of the company’s stock worth $3,706,000 after purchasing an additional 377,545 shares during the last quarter. Barclays PLC grew its position in Zura Bio by 777.1% in the 3rd quarter. Barclays PLC now owns 64,061 shares of the company’s stock worth $260,000 after purchasing an additional 56,757 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new stake in Zura Bio in the 3rd quarter worth $71,000. Braidwell LP acquired a new stake in Zura Bio in the 3rd quarter worth $10,040,000. Finally, State Street Corp grew its position in Zura Bio by 47.5% in the 3rd quarter. State Street Corp now owns 395,059 shares of the company’s stock worth $1,604,000 after purchasing an additional 127,300 shares during the last quarter. 61.14% of the stock is currently owned by institutional investors and hedge funds.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.